Profile data is unavailable for this security.
About the company
Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.
- Revenue in GBP (TTM)860.92m
- Net income in GBP-105.83m
- Incorporated2014
- Employees1.05k
- LocationIndivior PLC10710 Midlothian TurnpikeSuite 125, North ChesterfieldCHESTERFIELD 23235United StatesUSA
- Phone+0 (804) 379-1090
- Websitehttps://www.indivior.com/en
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North China Pharmaceutical Co Ltd | 1.08bn | 5.37m | 882.61m | 10.16k | 164.28 | 1.55 | -- | 0.8173 | 0.0293 | 0.0293 | 5.90 | 3.11 | 0.4721 | 2.78 | 4.30 | 995,956.10 | 0.4856 | -0.2978 | 1.14 | -0.7042 | 29.56 | 35.73 | 1.03 | -0.5985 | 0.5403 | 1.54 | 0.6491 | -- | -3.62 | 1.89 | 100.71 | -49.62 | 4.22 | -19.73 |
| Innoviva Inc | 248.05m | 109.15m | 885.57m | 112.00 | 11.41 | 1.77 | 6.37 | 3.57 | 1.65 | 1.65 | 4.15 | 10.64 | 0.2821 | 1.02 | 3.78 | 2,950,857.00 | 12.41 | 26.24 | 12.78 | 28.53 | 87.06 | -- | 44.00 | 76.84 | 11.40 | -- | 0.4019 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Polypeptide Group AG | 273.44m | -23.86m | 892.32m | 1.28k | -- | 2.95 | 470.11 | 3.26 | -0.8195 | -0.8195 | 9.41 | 10.33 | 0.522 | 1.92 | 4.90 | 257,777.60 | -4.55 | 2.59 | -6.20 | 3.26 | 9.26 | 23.73 | -8.73 | 4.58 | 0.7224 | -0.8348 | 0.2434 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
| Chongqing Genrix Biophrmctcl Co Ltd | 116.48k | -82.72m | 897.36m | 547.00 | -- | 3.36 | -- | 7,704.12 | -2.11 | -2.11 | 0.003 | 6.81 | 0.0003 | 0.0628 | 53.97 | 1,995.17 | -20.89 | -- | -21.71 | -- | -214.22 | -- | -71,021.27 | -- | 20.06 | -- | 0.2053 | -- | 154.92 | -- | -39.03 | -- | -- | -- |
| Aurisco Pharmaceutical Co Ltd | 153.74m | 40.78m | 899.99m | 1.52k | 22.25 | 4.05 | -- | 5.85 | 0.9328 | 0.9328 | 3.50 | 5.12 | 0.5744 | 1.15 | 5.11 | 947,099.20 | 15.19 | 12.40 | 19.04 | 14.33 | 58.12 | 51.26 | 26.44 | 23.05 | 1.33 | -- | 0.1447 | 25.15 | 25.24 | 17.02 | 37.23 | 16.16 | 26.54 | -- |
| Indivior PLC | 860.92m | -105.83m | 902.28m | 1.05k | -- | -- | -- | 1.05 | -0.8162 | -0.8162 | 6.08 | -0.6778 | 0.7024 | 1.29 | 4.70 | 819,139.20 | -8.63 | 1.32 | -22.00 | 2.62 | 83.00 | 83.69 | -12.29 | 2.68 | 0.6848 | -- | 1.76 | 0.00 | 21.31 | 1.69 | 96.00 | -- | 5.27 | -- |
| Kissei Pharmaceutical Co Ltd | 401.45m | 62.22m | 903.76m | 1.78k | 13.17 | 0.7109 | 10.61 | 2.25 | 268.51 | 268.51 | 1,728.18 | 4,972.53 | 0.3204 | 1.55 | 2.90 | 43,524,450.00 | 5.00 | 3.61 | 5.38 | 3.90 | 49.90 | 49.47 | 15.59 | 12.69 | 4.93 | -- | 0.006 | 34.87 | 11.98 | 0.8919 | 6.00 | 15.28 | 6.58 | 10.40 |
| ANI Pharmaceuticals Inc | 404.50m | 17.22m | 904.09m | 642.00 | 48.17 | 2.65 | 14.14 | 2.24 | 1.19 | 1.19 | 27.93 | 22.81 | 0.6055 | 1.81 | 3.18 | 839,490.60 | 3.04 | -2.83 | 3.56 | -3.35 | 61.34 | 60.18 | 5.01 | -6.15 | 3.07 | 3.10 | 0.3725 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Collegium Pharmaceutical Inc | 432.80m | 74.97m | 904.23m | 197.00 | 16.28 | 5.58 | 4.95 | 2.09 | 2.30 | 2.30 | 12.43 | 6.70 | 0.5087 | 8.14 | 3.28 | 2,927,173.00 | 8.81 | 2.79 | 14.58 | 4.80 | 61.94 | 50.88 | 17.32 | 5.16 | 1.04 | 3.69 | 0.7185 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Neuren Pharmaceuticals Ltd | 104.56m | 60.06m | 905.21m | -- | 15.09 | 8.07 | 15.07 | 8.66 | 0.9163 | 0.9163 | 1.58 | 1.71 | 1.25 | -- | 16.04 | -- | 72.03 | 49.80 | 75.50 | 55.37 | -- | -- | 57.44 | 50.10 | -- | -- | 0.00 | 0.00 | 1,403.22 | 76.78 | 85,270.11 | 119.64 | -- | -- |
| Calliditas Therapeutics AB | 118.06m | -35.41m | 912.10m | 222.00 | -- | 104.39 | -- | 7.73 | -8.95 | -8.95 | 29.83 | 1.98 | 0.9267 | 3.62 | 8.68 | 8,212,380.00 | -27.80 | -26.46 | -35.11 | -30.27 | 93.46 | -- | -30.00 | -76.59 | 2.59 | -3.07 | 0.9042 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| Avadel Pharmaceuticals PLC (ADR) | 71.41m | -79.72m | 916.90m | 154.00 | -- | 17.37 | -- | 12.84 | -1.17 | -1.17 | 1.04 | 0.7306 | 0.5308 | 0.6941 | 5.41 | 617,850.60 | -59.26 | -40.21 | -80.97 | -47.99 | 94.62 | -- | -111.64 | -374.75 | 2.52 | -10.25 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
Data as of Sep 26 2024. Currency figures normalised to Indivior PLC's reporting currency: UK Pound GBX
51.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Two Seas Capital LPas of 20 Jun 2024 | 13.26m | 9.98% |
| Morgan Stanley & Co. International Plcas of 31 Dec 2023 | 9.74m | 7.33% |
| Oaktree Capital Management LPas of 09 Jul 2024 | 9.38m | 7.06% |
| Soci�t� G�n�rale Gestion SAas of 02 Jul 2024 | 6.77m | 5.09% |
| Scopia Capital Management LPas of 19 Mar 2024 | 6.29m | 4.73% |
| Fidelity Management & Research Co. LLCas of 31 Jul 2024 | 5.13m | 3.87% |
| Barclays Capital Securities Ltd.as of 30 Jun 2024 | 4.64m | 3.49% |
| Madison Avenue Partners LPas of 14 Nov 2023 | 4.63m | 3.48% |
| The Vanguard Group, Inc.as of 31 Aug 2024 | 4.59m | 3.45% |
| BlackRock Investment Management (UK) Ltd.as of 31 Aug 2024 | 3.87m | 2.91% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
